Results 201 to 210 of about 411,114 (243)

OCTN2 Activates a Non‐Canonical Carnitine Metabolic Pathway to Promote MASH‐HCC Progression and Immunotherapy Resistance

Advanced Science, EarlyView.
In non‐MASH‐HCC, L‐carnitine promotes tumor progression primarily through its classical role in enhancing fatty acid oxidation (FAO). However, in MASH‐HCC, where FAO is markedly suppressed, L‐carnitine shifts from this canonical function to serve instead as an intracellular acetyl group buffer.
Chuqi Xia, Xiao Zhang, Jinze Li, Ning Xu, Sheng Hu, Qiyu Lu, Yuxuan Li, Taifu Xiao, Xu Li, Xue Wang, Kequan Xu, Daoming Liang   +11 more
wiley   +1 more source

Deep learning-based assessment of PD-L1 expression in NSCLC predicts outcome for patients treated with anti-PD-1 immunotherapy. [PDF]

Front Immunol
Peroz M, Roussot N, Ilie A, Rageot D, Derangere V, Truntzer C, Ghiringhelli F.   +6 more
europepmc   +1 more source

Conversion of Transplanted Mature Hepatocytes into Afp+ Reprogrammed Cells for Liver Regeneration After Injury

Advanced Science, EarlyView.
Donor‐derived tdTomato+ mature hepatocytes were FACS‐isolated and transplanted into Fah−/− host mice. During regeneration, these cells convert into proliferative, unipotent Afp+ rHeps. Their plasticity is governed by a PPARγ/AFP‐dependent metabolic switch, segregating into pro‐proliferative Afplow and pro‐survival Afphigh subpopulations.
Ting Fang, Chao Yang, Hua Qiu, Yuan Du, Xicheng Wang, Yuting Li, Mingyang Xu, Changcheng Liu, Xiuhua Li, Na Guo, Jun Shi, Wencheng Zhang, Zhiying He   +12 more
wiley   +1 more source

Prognostic value of PD-L1 expression on tumor-infiltrating immune cells and neutrophil-to-lymphocyte ratio in patients with biliary tract cancer. [PDF]

Front Immunol
Chen S, Huang G, Yao Z, Lin X, Cao J.
europepmc   +1 more source

PD-L1-targeted photodynamic therapy orchestrates checkpoint blockade and immunogenic cell death for synergistic cancer immunotherapy. [PDF]

Redox Biol
Liu S, Yang Z, Wang B, Huan S, Li Z, Wei X, Liu G.   +6 more
europepmc   +1 more source

Circulating sPD-L1 as a tumor microenvironment-derived biomarker: enhancing diagnostic discrimination accuracy in breast cancer. [PDF]

Cancer Immunol Immunother
Zhang Y, Chen S, Ma J, Sun X, Zhou X.
europepmc   +1 more source

Treatment patterns and clinical outcomes according to PD-L1 status in >2000 patients with early-stage or metastatic triple-negative breast cancer treated in the real-world setting: VANESSA study results. [PDF]

Breast
Popovic L, Barroso-Sousa R, El Saghir NS, Dent R, Tuzlali S, Akhtar S, Juozaityté E, Eglitis J, Doval DC, Castaneda CA, Zirtiloglu A, Hartleben G, Deurloo R, Toro P, Estaytieh I, Weber E, Mouta J, D'Arrigo C.   +17 more
europepmc   +1 more source

PD-1/PD-L1 blockade in HIV-associated advanced lung cancer: from mechanisms to clinical practice. [PDF]

Front Immunol
Chen R, Ren S, Tang H, Wu Q.
europepmc   +1 more source

Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial.

BMJ
Peng Z, Zhang Y, Xu H, Yang Y, Yang M, Zhang M, Cheng Y, Chen X, Pan Y, Wang F, Li Q, Xu N, Liu L, Gu K, Xiao J, Zhang R, Zhao Q, Chen J, Lin L, Chen Y, Deng Y, Cai S, Bai B, Wang Y, Shen L.   +24 more
europepmc   +1 more source